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In chronic kidney disease, functional impairment correlates
with tubulointerstitial fibrosis characterised by inflammation,
accumulation of extracellular matrix, tubular atrophy and
rarefaction of peritubular capillaries. Loss of the
microvasculature implies a hypoxic milieu and suggested an
important role for hypoxia when the ‘‘chronic hypoxia
hypothesis’’ was proposed a decade ago as an explanation
for the progressive nature of fibrosis. Recent data in man
provide evidence of decreased renal oxygenation in chronic
kidney disease while more direct support for a causal role
comes from data in rodent models showing that the decline
in renal oxygenation precedes matrix accumulation,
suggesting hypoxia may both initiate and promote the
fibrotic response. Indeed, in vitro studies show that hypoxia
can induce pro-fibrotic changes in tubulointerstitial cells.
Additional postulated roles for hypoxia in chronic kidney
disease are the sustaining of the inflammatory response, the
recruitment, retention and differentiation towards a
pro-fibrotic phenotype of circulating progenitor cells and the
alteration of the function of intrinsic stem cell populations.
Given that accumulating data suggests that chronic hypoxia
is a final common pathway to end-stage renal disease,
therapeutic strategies that target hypoxia may be of benefit
in retarding progression. Normalisation of microvascular
tone, administration of pro-angiogenic factors to restore
microvasculature integrity, activation of hypoxia-inducible
transcription factors and hypoxia-mediated targeting and
mobilisation of progenitor cells are all potential targets for
future therapy. The limited success of existing strategies in
retarding chronic kidney disease mandates that these new
avenues of treatment be explored.
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CHRONIC KIDNEY DISEASE AND RENAL FIBROSIS
Renal fibrosis is the hallmark of chronic kidney diseases
(CKDs) of diverse etiologies in which accumulation of
extracellular matrix (ECM) disrupts normal tissue architec-
ture leading to progressive renal dysfunction and organ
failure.1 Regardless of the initiating insult, CKD presents a
common pathology of glomerulosclerosis and tubulointer-
stitial fibrosis and it is well established that tubulointerstitial
fibrosis provides the best predictive indicator of progression
to end-stage disease. Tubulointerstitial fibrosis presents a
number of characteristic features1 including an inflammatory
cell infiltrate, which results from both activation of resident
inflammatory cells and recruitment of circulating inflamma-
tory cells; an increase in interstitial fibroblasts due to
increased proliferation and decreased apoptosis of resident
interstitial cells as well as recruitment of cells to the
tubulointerstitium; the appearance of myofibroblasts expres-
sing the cytoskeletal protein a-smooth muscle actin, which
arise by differentiation of resident interstitial fibroblasts and
infiltrating cells and via transdifferentiation;2 accumulation
of ECM as the net result of increased production and
decreased turnover of matrix proteins; tubular atrophy as a
consequence of apoptosis and epithelial–mesenchymal trans-
differentiation (EMT); and, rarefaction of peritubular
capillaries.1 The development of fibrosis is associated with
an increase in expression of proinflammatory, vasoconstric-
tive, and profibrotic factors (including transforming growth
factor (TGF)-b1 connective tissue growth factor, platelet-
derived growth factor, fibroblast growth factor-2, endothelin
(ET)-1, and angiotensin II), which is paralleled by a decrease
in antifibrotic factors (such as hepatocyte growth factor, and
bone morphogenetic protein-7).1,2
HYPOXIA AND FIBROSIS
Detailed examination of biopsies of patients with CKD
showed marked rarefaction of peritubular capillaries.3 Loss of
the microvasculature implies a hypoxic milieu and suggested
an important role for hypoxia when the ‘chronic hypoxia
hypothesis’ was proposed a decade ago as a mechanism by
which glomerular injury is transmitted to the tubulointerstitium
and sets in train the progressive scarring and decline in renal
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function.4 The hypothesis proposed that primary glomerular
disease leads to restricted postglomerular flow from affected
glomeruli and downstream injury to the peritubular capillary
network (Figure 1). Microvasculature dysfunction creates a
hypoxic environment that triggers a fibrotic response in
tubulointerstitial cells. This, in turn, impacts on adjacent
previously unaffected capillaries, nephrons and glomeruli,
exacerbating injury, extending the regions of hypoxia, and
setting up an inexorable cycle of destruction to organ failure.
Data from animal models have established a direct correla-
tion between rarefaction of the peritubular capillaries and
development of glomerular and tubulointerstitial scarring.5
However, before dropout of capillaries, other mechanisms
may contribute to decreased tissue oxygenation including
anemia, increased vasoconstriction driven by an increase in
vasoconstrictors and/or loss of vasodilators, increased meta-
bolic demand as a result of hyperfiltration and hypertrophy
of uninjured nephrons, and increased oxygen diffusion
distances as ECM accumulates between blood vessels and
adjacent cells.6–8
EFFECTS OF HYPOXIA ON TUBULOINTERSTITIAL CELLS
Support for a causal role of hypoxia in fibrosis comes from in
vitro studies of the effect of hypoxia on tubular epithelial cells
and interstitial fibroblasts that, as described above, undergo a
series of characteristic changes in fibrosis.
Studies on tubular epithelial cells have largely focused on
proximal tubular epithelial cells (PTE) as the predominant
epithelial cell type in the cortex and susceptible to hypoxic
injury. In PTE, hypoxia induces a complex transcriptional
response with changes in expression of a large number of
genes involved in cell survival and adaptation.9 Although a
number of transcription factors have been shown to be
activated by hypoxia,10 the hypoxia-inducible factor (HIF)
family are considered master regulators of the adaptive
response controlling expression of hundreds of genes.7,10,11
HIFs are heterodimeric transcription factors comprising a
constitutively expressed b-subunit and an oxygen-regulated
a-subunit. In normoxia, stability, and activity of the
a-subunit is regulated by oxygen-dependent hydroxylation
of proline and asparagine residues by prolyl hydroxylase 2
and factor inhibiting HIF-1, respectively. In hypoxia, HIFa
proteins are stabilized, dimerize with HIFb and bind to
hypoxia-response elements in the regulatory regions of target
genes.7,10,11 Three mammalian a-subunits have been identi-
fied: HIF-1a, HIF-2a (EPAS), and HIF-3a (IPAS). Study has
largely concentrated on HIF-1a and HIF-2a, HIF-3a is less
well characterized but a splice variant has been suggested to
act as an intrinsic repressor of the HIF pathway. HIF-1a and
HIF-2a appear to have both unique and overlapping
functions and to act in a cell type- and stimulus-specific
manner.7,11 In the hypoxic kidney, HIF-1a accumulates in
tubules and in papillary interstitial cells whereas HIF-2a is
induced in peritubular endothelial cells and fibroblasts
(reviewed in Nangaku and Ekardt7).
Hypoxia alters PTE matrix metabolism, promoting ECM
accumulation with a switch to production of interstitial
collagen and suppression of matrix degradation.8 EMT is
increasingly implicated in fibrosis;2 exposure of PTE to
hypoxia induces a myofibroblastic phenotype whereas more
prolonged exposure leads to mitochondrial injury and
apoptosis consistent with the loss of tubular cells in vivo.6–8
In PTE, hypoxia also induces expression of fibrogenic factors
including TGFb and ET-1 as well as angiogenic factors,
vascular endothelial growth factor and angiopoietin-4,
capable of acting as autocrine or paracrine mediators.6–8
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Figure 1 | Hypoxia and progression of CKD. Primary glomerular injury leads to changes in postglomerular peritubular hemodynamics
inducing endothelial injury and microvascular insufficiency, creating a hypoxic tissue environment and triggering tubular injury, EMT,
inflammation, recruitment of circulating precursors, myofibroblast differentiation, and fibrosis. The evolving inflammatory response and
accumulation of ECM impact on adjacent unaffected capillaries and tubules compromising the outflow tracts of previously intact glomeruli,
exacerbating injury and leading to progressive scarring and a loss of organ function. In addition to rarefaction of the microvasculature,
concomitant anemia, pathological vasoconstriction, increased oxygen diffusion distances due to ECM accumulation, and increased
metabolic demand of tubular cells may all contribute to localized tubulointerstitial hypoxia.
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Notably, although TGFb is induced by hypoxia in PTE, the
changes in ECM metabolism appear to occur via TGFb1-
independent mechanisms.8 In addition to directly inducing
fibrogenic changes, hypoxia can synergize with other known
fibrogenic stimuli to amplify the pathological response
(reviewed in Norman and Fine8).
Fibroblasts are the major ECM-producing cells in the
tubulointerstitium.1 In vitro, hypoxia promotes a fibrogenic
phenotype in these cells with increased proliferation,
enhanced myofibroblast differentiation and contraction,
and altered ECM metabolism; changes that are associated
with sustained activation of focal adhesion kinase and
downstream signaling pathways including those mediated
by the Ras guanosine triphosphatases and mitogen-activated
protein kinases.8 As in PTE, exposure to low oxygen increases
fibroblast ECM production, upregulating a variety of matrix
proteins.8 In addition, hypoxia upregulates enzymes involved
in post-translational modification of collagen, potentially
producing a matrix with altered mechanical properties and
resistant to degradation (reviewed in Norman and Fine8).
Some aspects of the fibrogenic phenotype induced by hypoxia
are likely due to the autocrine actions of hypoxia-induced
growth factors, however, transcriptional induction of col-
lagen type I by hypoxia is independent of TGFb. Further-
more, this transcriptional activation is HIF-independent and
regulated by the transcription factor, Sp1.8
In parallel with increased ECM production, hypoxia also
suppresses matrix degradation via decreased expression and
activity of matrix metalloproteinases, in particular interstitial
collagenase matrix metalloproteinase-1, and increased HIF-
dependent expression of the endogenous inhibitor tissue
inhibitor of metalloproteinase (TIMP)-1.8 Another family of
metalloproteases, the adamalysins, are involved in processing
of ECM proteins and shedding of cell-surface molecules.12
These proteases have not been widely studied in renal
pathophysiology, however members of adamalysin family are
regulated by hypoxia in renal fibroblasts (unpublished
observations) and may have as yet unexplored roles in
hypoxia-induced fibrosis.
Data from nonrenal fibroblasts suggest additional profi-
brotic effects of hypoxia in renal fibroblasts in suppressing
apoptosis,13 inducing production of proinflammatory fac-
tors14,15 and upregulating components of the renin–angio-
tensin system.16 Taken together, the in vitro data indicate that
hypoxia can, directly or indirectly, induce functional and
phenotypic changes in PTE and interstitial fibroblasts
consistent with changes seen in these cells in CKD.
Although endothelial cells of the peritubular capillaries are
a primary target for hypoxic injury in the kidney and
numerous studies have examined the response of a variety of
endothelial cell types to hypoxia, the hypoxic response in
renal microvascular endothelial cells is largely unexplored. As
hypoxia is classically a potent angiogenic stimulus the lack of
vascular repair in the hypoxic kidney may suggest that these
endothelial cells differ in their response to a low oxygen
milieu. Loss of endothelial cells in fibrotic kidneys5 implies
that the predominant response of renal endothelial cells to
hypoxia may be apoptosis. There is increasing evidence the
endothelial cells possess the capacity to transdifferentiate to
(myo)fibroblasts17 and it is interesting to speculate that in the
kidney, hypoxia might drive this process leading to disrup-
tion of peritubular capillaries, simultaneously exacerbating
tissue hypoxia and increasing the number of ECM-producing
fibroblasts. Another hypoxia-sensitive component of the
peritubular microvasculature, which may play an as yet
unappreciated role in renal fibrosis, are the pericytes,
contractile cells which surround the endothelial cells and
stabilize the vessels.18 These cells have the potential to
contribute to pathological vasoconstriction and also to ECM
accumulation as they too possess the capacity to differentiate
into synthetic (myo)fibroblast-like cells.19
HYPOXIA AS AN INFLAMMATORY STIMULUS
Persistent inflammation is considered to be an intrinsic
component of the fibrotic response.1 Hypoxia provides a
homing signal for inflammatory cells20 that accumulate at
sites of injury. It may also activate resident immune cells21
and as such may be an important inflammatory stimulus in
the setting of CKD particularly where, in the absence of
vascular regeneration, chronic hypoxia may potentiate an
ongoing proinflammatory response or impede resolution and
stimulate fibrosis. In addition, it has been suggested that
some inflammatory cells have the potential to differentiate
into fibroblasts and to contribute to pathological ECM
accumulation,19 whether hypoxia can drive this process is an
intriguing possibility which remains to be tested.
HYPOXIA AS A STIMULUS FOR PROGENITOR CELL
RECRUITMENT
In the fibrotic kidney a proportion of ECM-producing cells
are derived from circulating precursor cells.22 Although the
mechanisms of cell recruitment and retention within the
kidney have not been defined, a role for hypoxia seems
plausible as progenitor cells preferentially home to ischemic
sites through interactions between the CXCR4 chemokine
receptor and its ligand, stromal cell-derived factor-1, both of
which are HIF target genes.23 It is interesting to speculate that
once progenitor cells are recruited the hypoxic milieu within
the kidney may affect cell differentiation, potentially inducing
a profibrotic phenotype. Similarly, hypoxia may alter the
differentiation of intrinsic progenitor/stem cells such that
these cells contribute to the fibrotic process either directly or
indirectly by failure to repair injury.
IN VIVO EVIDENCE FOR HYPOXIA IN CKD
Since the introduction of the ‘chronic hypoxia hypothesis’,4
an increasing number of studies in animal models have
shown an association between hypoxia and CKD (Table 1)
(reviewed in Nangaku,6 Nangaku and Eckardt,7 and Norman
and Fine,8 see also Rosenberger et al.24 and Bernhardt et al.25)
with the early decline in tissue oxygenation suggesting a
causal relationship. A variety of different techniques have
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been used to measure tissue oxygenation (Table 1). Histori-
cally oxygen microelectrodes have been widely used in studies
of renal oxygenation and have demonstrated the presence of
hypoxia in diabetic nephropathy.6–8 However, in the context
of animal models of CKD, the most commonly used method
to evaluate hypoxia is immunohistochemical detection of
hypoxia-dependent pimonidazole proteins adducts. Pimoni-
dazole staining has revealed the early presence of hypoxia in
uninephrectomy and anti-Thy1 glomerulonephritis, the
remnant kidney, diabetic nephropathy,24 cyclosporine ne-
phropathy, the aging kidney and polycystic kidney disease
(PKD) in the rat,25 and in murine models including folic acid
nephropathy, adriamycin nephrosis, and unilateral ureteral
obstruction.6–8 The limitation of this approach is that
pimonidazole forms adducts at PO2 o10 mm Hg and thus
is nonquantitative. Imaging techniques such as blood
oxygen-dependent magnetic resonance imaging may provide
quantitative information on renal oxygenation and have been
used to show hypoxia in the diabetic kidney.8 The hypoxia-
sensing transgenic rat expressing a hypoxia-response ele-
ment-driven luciferase vector provides a novel means to
examine the patterns of renal hypoxia and has been used to
demonstrate the presence of hypoxia in puromycin amino-
nucleoside nephrosis and in the aging kidney,7 which displays
many of the histological features of CKD including loss of
peritubular capillaries. Further, hypoxia was detected in aging
kidneys with only mild tubulointerstitial disease indicating
that similar to the findings in CKD hypoxia occurs early in
the development of the fibrosis and correlates with the degree
of tubulointerstitial injury, suggesting a causal role for
hypoxia in age-related fibrotic renal disease.
The accumulating data from animal models provide a
compelling argument for hypoxia as a primary mediator of
progressive scarring in the kidney, however the key question
is whether this also applies in humans. Although there are
currently only limited clinical data, increased expression of
HIF has been reported in biopsies of patients with diabetic
nephropathy,26 immunoglobulin A nephropathy, PKD,25 and
chronic allograft nephropathy27 suggesting the presence of
hypoxia in these disease settings and supporting the idea that
hypoxia is an important contributory factor in the pathogen-
esis of CKD in humans. Furthermore, the changes in HIF
expression correlate with the extent of tubulointerstitial
injury. The majority of studies in human samples have used
immunohistochemical detection of HIFs as a surrogate
marker of hypoxia. A potential limitation of this approach
is that although HIFs are clearly induced by hypoxia, non-
hypoxic stabilization of HIF has also been reported. More-
over in animal models only partial overlap of pimonidazole
and HIF signals is observed, thus, immunohistochemical data
need to be verified by more direct measurements of tissue
oxygenation.
CHRONIC HYPOXIA AS A THERAPEUTIC TARGET IN CKD
The central role for hypoxia in renal fibrosis suggests that
therapeutic manipulation of the hypoxic response may be of
benefit in preventing or retarding disease.6–8 Approaches to
ameliorate hypoxia-mediated profibrotic changes induced
include correction of anemia (not discussed here); normal-
ization of vascular tone and intrarenal microvascular
perfusion; preservation, repair, and stabilization of the
tubulointerstitial microvasculature; stabilization of HIF in
the tubulointerstitium; and, manipulation of hypoxia-
induced cell homing.
Normalization of vascular tone and improved intrarenal
microvascular perfusion by alleviating vasoconstriction and/
or enhancing vasodilation is a logical goal. Activation of the
rennin–angiotensin system has long been implicated in the
pathogenesis of renal fibrosis and the therapeutic efficacy of
angiotensin-converting enzyme inhibition and angiotensin
receptor blockade is well established. Importantly, in the rat
remnant kidney, administration of an angiotensin-converting
enzyme inhibitor and an angiotensin receptor blockade
restored cortical perfusion and reduced tissue hypoxia
thereby extending the possible range of renoprotective
mechanisms exerted by these classes of agents.6,7 ET, another
potent vasoconstrictor, is also overexpressed in fibrosis;
selective and nonselective ET receptors antagonists have been
developed and show renoprotective effects in animal models.
In particular, selective antagonism of ET-A receptors may
have maximal benefit to decrease ET-mediated vasoconstric-
tion and block direct fibrogenic effects of ET while leaving
intact ET-B receptor-mediated functions. On the other hand,
to promote vasodilation it may also be possible to enhance
NO signaling which is compromised in the setting of fibrosis.
Loss of the peritubular capillaries is a hallmark of renal
fibrosis and was the observation that initiated the investiga-
tion of the potential role of hypoxia in renal scarring. In
tumors, hypoxia is a potent angiogenic stimulus inducing a
range of angiogenic factors and one of the anomalies in
Table 1 | In vivo evidence of hypoxia in CKD
Method for detecting hypoxia Species Disease model
Porphyrin phosphorescence Rat Antiglomerular basement
membrane antibody
Pimonidazole protein adduct
histochemistry
Rat Uninephrectomy+anti-Thy-1
antibody
Remnant kidney
Diabetic nephropathy
Cyclosporin A-induced
nephropathy
Aging kidney
Polycystic kidney disease
Mouse Folic acid nephropathy
Adriamycin nephrosis
Unilateral ureteral
obstruction
Hypoxia-sensing transgenic rat Rat Remnant kidney
Puromycin aminonucleoside
nephrosis
Aging kidney
Blood oxygen-dependent
magnetic resonance imaging
Rat Diabetic nephropathy
Clarke-type microelectrode Rat Diabetic nephropathy
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considering hypoxia as a fibrogenic stimulus is the apparent
failure of angiogenic repair in the hypoxic kidney. In models
of CKD, although there is an early, transient increase in
vascular endothelial growth factor, levels of expression are
reduced in advanced disease.5 The mechanism for this
reduction is unclear but it appears to correlate with
inflammatory cell infiltration and may relate to tubular
atrophy as PTEs are an important source of vascular
endothelial growth factor.8 Interestingly, a recent in vitro
study suggests that under hypoxic conditions albumin
suppresses vascular endothelial growth factor production by
tubular cells, providing a possible link between proteinuria
and hypoxia in CKD and evidence of a potentially important
interaction between tubular epithelial cells and microvascular
endothelial cells in the setting of hypoxia although it should
be noted that the concentrations of albumin used were high
and equivalent to plasma concentrations.28 Expression of
another angiogenic factor, angiopoietin-1, is also suppressed
in a mouse model of CKD,29 suggesting an overall reduction
in proangiogenic factors.
In parallel, an increase in anti-angiogenic factors may also
contribute to failure of angiogenic repair as at least two
matricellular proteins upregulated in fibrosis have anti-
angiogenic activity30 and, at least in some cell types,
expression of an endogenous inhibitor of angiogenesis,
endostatin, is increased by hypoxia.31 Thus preservation,
repair, and stabilization of the tubulointerstitial microvascu-
lature by administration of exogenous angiogenic factors5,29
or inhibition of endogenous inhibitors may represent
promising therapeutic strategies although as highlighted by
a recent reports that showed variable outcomes of angio-
poietin-1 therapy in different models,29,32 the clinical efficacy
of angiogenic factor therapy will depend on a detailed
understanding of the role of such factors in the pathogenesis
of CKD in humans.
HIF is a major regulator of the adaptive response to
hypoxia and several lines of evidence suggest that activation
of HIF pathway may be renoprotective. Consistent with a
protective role for HIF, activation of HIF by cobalt chloride,
carbon monoxide, or inhibition of prolyl hydroxylase has
been shown to attenuate injury in a number of different
disease models including ischemic injury, cisplatin nephro-
pathy, acute and progressive glomerulonephritis, the remnant
kidney (reviewed in Nangaku,6 Nangaku and Eckardt,7 and
Norman and Fine,8 see also Weidemann et al.33). Conversely,
genetic deficiency in HIF was found to exacerbate ischemic
injury.34 Collectively, these data suggest that activation of
HIF protects the kidney against injury induced by a variety of
stimuli and points to this system as a potential therapeutic
target. In terms of clinical applications, the toxicity of cobalt
chloride precludes its therapeutic use and a more promising
approach may be to stabilize HIF by blocking prolyl
hydroxylase activity, a number of inhibitors are under
development with initially promising results.35 Blockade of
factor inhibiting HIF and gene transfer may provide
additional alternative strategies to activate the HIF pathway.
Although the therapeutic potential of activation of the
HIF pathway in CKD has elicited considerable interest, a note
of caution needs to be sounded with the recent demonstra-
tion that cell-specific activation of HIF in podocytes induces
rapidly progressive glomerulonephritis and renal failure;36
that HIF drives EMT;26 and, that HIF activates profibrotic
genes.6–8 Further, deletion of Hif1a in tubular epithelial cells
has been shown to reduce fibrosis in the unilateral ureteral
obstruction model of CKD.26 Given that activation of HIF
appears to have both cytoprotective and profibrotic effects,
potential therapeutic strategies that target the HIF signaling
pathway will require careful evaluation. A particular
challenge will be to develop drugs that preferentially stabilize
HIF in the kidney to avoid the potentially detrimental effects
of widespread activation of this system.
A more speculative therapeutic aspect of the hypoxic
response is the manipulation of hypoxia-induced cell homing
to prevent homing, retention, and/or differentiation of
fibrogenic precursor cells within the kidney. Conversely, an
intriguing possibility is that hypoxia-mediated recruitment
and differentiation mechanisms can be used to selectively
direct progenitor cells and genetically-engineered precursors
to the kidney and to sites of injury to either inhibit fibrosis or
promote regression.
CONCLUSION
The ‘chronic hypoxia hypothesis’ was first put forward in
1998,4 in the ensuing decade a substantial body of evidence
has accumulated from in vitro studies, from in vivo models,
and, more recently, from studies in humans to place hypoxia
at the center of ideas on mechanisms of progression of CKD.
A detailed understanding of the role of hypoxia in fibrosis
and the interaction of hypoxia with other factors influencing
progression opens the door to a variety of novel therapeutic
strategies aimed at preventing or retarding a wide range of
intractable kidney diseases.
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